Form 8-K OCULAR THERAPEUTIX, INC For: Mar 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
March 3, 2025 11:48 AM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Ocular Therapeutix (NASDAQ: OCUL) to $17.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "Ocular (OCUL) reported an amendment to the SPA for SOL-1 to include re-dosing at weeks 52 and 76. Mgmt underscored the 9-month... More
